Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Cash (2016 - 2025)

Historic Change in Cash for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to -$59.3 million.

  • Summit Therapeutics' Change in Cash fell 19077.5% to -$59.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.8 million, marking a year-over-year increase of 10592.41%. This contributed to the annual value of $33.8 million for FY2024, which is 10584.95% up from last year.
  • Summit Therapeutics' Change in Cash amounted to -$59.3 million in Q3 2025, which was down 19077.5% from $86.3 million recorded in Q2 2025.
  • Summit Therapeutics' Change in Cash's 5-year high stood at $526.6 million during Q4 2022, with a 5-year trough of -$577.6 million in Q1 2023.
  • For the 5-year period, Summit Therapeutics' Change in Cash averaged around $9.1 million, with its median value being $1.2 million (2021).
  • As far as peak fluctuations go, Summit Therapeutics' Change in Cash skyrocketed by 632722.01% in 2022, and later plummeted by 1030742.18% in 2023.
  • Over the past 5 years, Summit Therapeutics' Change in Cash (Quarter) stood at -$8.5 million in 2021, then skyrocketed by 6327.22% to $526.6 million in 2022, then plummeted by 90.96% to $47.6 million in 2023, then crashed by 76.72% to $11.1 million in 2024, then plummeted by 634.91% to -$59.3 million in 2025.
  • Its last three reported values are -$59.3 million in Q3 2025, $86.3 million for Q2 2025, and $106.7 million during Q1 2025.